- Source : Business Wire
- Date : 2021-07-20
- Companies : Infectolab Americas
Minnesota-Based Laboratory Infectolab Americas Releases COVID-19 T-Cell Test on Monday the 26th of July
OAKDALE, Minn.--(BUSINESS WIRE)--Infectolab Americas, an infectious disease testing laboratory from Oakdale in Minnesota that is specialized in antigen specific T-cell testing for infectious diseases, has validated a novel T-cell test for COVID-19. The technology is based on stimulating antigen specific T-cells in vitro and enumerating the antigen specific T-cells to a given antigen. The novel T-cell test for SARS-CoV-2 can help monitor cellular immunity against COVID-19 and offers greater detail to the immune status of long-haul patients.
Studies on antigen specific SARS-CoV-2 T-cells have shown that testing for Interferon-γ and IL-2 release can provide important information about cellular immunity post-infection and vaccine efficacy. A recent study published by Zuo et al. in Nature Immunology shows that 6 months post-infection Interferon-γ and IL-2 producing antigen specific T-cells were present in the patients (1). They showed that the severity of the disease appears to have played a role in the number of T-cells present 6 months post-disease.
In our mRNA vaccine study, we could show that 3 months post-mRNA vaccine antigen specific central memory T-cells and antigen specific TH-1 T-cells were present in the participants blood indicating the potential of a long-term cellular memory response to the vaccine.
Infectolab Americas SARS-CoV-2 T-cell test provides an insight into the T-cells of COVID-19 patients and vaccinated individuals. The test has 3-4-day turnaround time and offers comprehensive reporting that gives information about the amount of SARS-CoV-2 antigen specific TH-1 T-cells and central memory T-cells.
Having a quick T-cell test available for COVID-19 infected patients and also a test where vaccinated people can find out how likely it is that they have developed cellular immunity in addition to humoral immunity, can help guide treatment and ease many concerns. “The pandemic has been an extremely challenging time for all of us and Infectolab Americas is proud to be able to introduce a neat tool like this, that can help give us a better understanding of the immune system response to the infection and the vaccination for COVID-19,” said Dr. Felix Scholz, PhD, President of Infectolab Americas.
About Infectolab Americas:
Infectolab Americas supports health care practitioners with diagnosing and monitoring infections appropriately by providing the most accurate laboratory results possible. Their focus is on delivering quality laboratory performance and guaranteeing a superior sample output; this includes quick same day or overnight shipping and a rapid turnaround time on results that health care practitioners can access immediately via a secure online portal.
Benefits of our COVID-19 T-cell test:
- Check and monitor T-cell responses in infections
- Check the efficacy of vaccines
- Check on long haul COVID patients
For more information and questions please contact Felix Scholz, PhD under [email protected] or call 651-387-2614
Felix Scholz, PhD